This Growth REIT Hasn’t Seen Share Price Growth


Download our exclusive REIT Report

Different from several multifamily REITs, Bluerock Residential Growth REIT hasn’t seen its share price soar in 2016. It also has a noticeably higher yield than its peers. Eventually, the company has faced the challenges typical of other similar, small cap REITs, including higher leverage, frequent public offerings, and building a long-term investor base.

Even with the steep growth over the past quarters, it has been eye-catching that the share hasn’t managed to make up some ground. In fact, its share price has fallen by 14% over the past year, while the company doubled its net operating income. Today, the stock is trading with a dividend yield close to 10%, which always tops our dividend yield ranking for the sector.

In order to fuel its expansion, the company hasn’t been shy, opting to capitalize on several funding fronts. In 2015, they performed three public offerings. In addition, they have diversified their sources of funding by issuing preferred shares. They also pushed the debt levels up higher and closed Q1 with a total debt to total enterprise value of 58%.

With a market cap just under $300 million, the company is looking to form a solid institutional investor base that can support its continued growth. Currently, less than 50% of the shares are held by institutional and mutual fund owners. As a result, it appears that the company still has a long way to go to complete its task compared to established REITs.

chart02.pngThere are reasons to believe this REIT might struggle to get more support, primarily because it is externally advised and it makes distributions beyond its adjusted funds from operations. On the other hand, the company has made its presence known in sunbelt markets, where job growth has been prominent.

To summarize, Bluerock Residential is hungry to grow and seems to be hitting the right nails. However, due to its shortcomings, it hasn’t managed to convince enough investors to back its aggressive growth plans yet. The stock is a patient buy.

Source: Bluerock Residential Growth RE(AMEX:BRG), Fast Graphs, Yahoo!Finance

Disclaimer: This newsletter is not engaged in rendering tax, accounting, or other professional advice through this publication. No statement in this issue is to be construed as a recommendation to buy or sell any security or other investment. Please do your own due diligence before making any investment decision. Some information presented in this publication has been obtained from third-party sources considered to be reliable. Sources are not required to make representations as to the accuracy of the information, however, and consequently the publisher cannot guarantee accuracy.

Disclosure: The author has no positions in any shares mentioned, and no plans to initiate any positions within the next 72 hours.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s